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ender-Based Outcomes After
aclitaxel-Eluting Stent Implantation
n Patients With Coronary Artery Disease
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OBJECTIVES We sought to determine whether gender influences the results of paclitaxel-eluting stent
implantation.
BACKGROUND The TAXUS-IV trial demonstrated the safety and effectiveness of the slow-release, polymer-
based, paclitaxel-eluting TAXUS stent compared to bare-metal stents in patients undergoing
elective coronary intervention. Whether these results are generalizable to women is not known.
METHODS A total of 1,314 patients with coronary lesions 10- to 28-mm long in 2.5- to 3.75-mm vessels
were randomized to TAXUS stent versus bare-metal EXPRESS stents (Boston Scientific
Corp., Natick, Massachusetts). Outcomes examined were stratified by gender.
RESULTS A total of 662 patients (including 187 women) were assigned to the TAXUS stent, and 652
(180 women) received the control stent. Women were older than men, and had more
hypertension, diabetes, renal insufficiency, unstable angina, and heart failure, but less
smoking. Among patients receiving the TAXUS stent, women compared with men had
higher unadjusted one-year rates of target lesion revascularization (TLR) (7.6% vs. 3.2%, p
0.03), though female gender was not an independent predictor of TLR (odds ratio [OR] 
1.72 [95% confidence interval (CI) 0.68 to 4.37], p  0.25). Moreover, restenosis rates were
similar in men and women treated with the TAXUS stent (8.6% vs. 7.6%, respectively, p 
0.80), as was late loss (0.22 vs. 0.23 mm, p  0.90). Compared to control stents, treatment
with the TAXUS stent in women resulted in a significant reduction in nine-month restenosis
(8.6% vs. 29.2%, p  0.0001) and one-year TLR (7.6% vs. 14.9%, p  0.02). The only
independent predictor of freedom from restenosis in women was randomization to the
TAXUS stent (OR  0.28 [95% CI 0.11 to 0.74], p  0.01).
CONCLUSIONS The benefits of the paclitaxel-eluting stent in reducing clinical and angiographic restenosis are
generalizable to women. (J Am Coll Cardiol 2005;45:1180–5) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.076College of Cardiology Foundation
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dtents reduce clinical and angiographic restenosis compared
o balloon angioplasty and other devices (1–3). Specific
ender-based comparisons were not reported from these
arlier randomized clinical trials, yet the results with bare-
etal stents have been generalized to the female population.
espite stent implantation, a considerable number of pa-
ients still develop restenosis and require repeat revascular-
zation within 6 to 12 months (4–6). Drug-eluting stents
hat deliver bioactive agents directly to the site of vascular
njury have demonstrated superior results in the elective
reatment of de novo coronary lesions compared to bare-
etal stents (7–16). Whether these devices are as safe and
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ccepted October 25, 2004.ffective in men and women is unknown. We report the
ender-based outcomes with the slow-release, polymer-
ased, paclitaxel-eluting TAXUS stent as evaluated in the
AXUS-IV clinical trial (12,16).
ETHODS
he TAXUS-IV study design, major inclusion and exclu-
ion criteria, end point definitions, and principal results have
een reported in detail previously (12). In brief, 1,314
atients undergoing elective coronary intervention of a
ingle de novo coronary lesion were prospectively random-
zed in double-blind fashion to the TAXUS stent, or an
dentical-appearing bare-metal EXPRESS stent (Boston
cientific Corp., Natick, Massachusetts). By visual estima-
ion the lesion lengths were 10 to 28 mm, with reference
essel diameters of 2.5 to 3.75 mm. Patients were stratified
uring randomization according to the presence or absence
f diabetes mellitus and vessel size. Diabetes, hyperlipid-
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ent for therapy with medications.
The recommended adjunctive pharmacologic regimen
ncluded 325 mg aspirin per day (continued indefinitely),
nd 300 mg of clopidogrel started before the procedure and
ontinued for at least six months. The procedural anti-
hrombotic agent used was unfractionated heparin, and
lycoprotein IIb/IIIa inhibitors were used at the operator’s
iscretion.
Clinical follow-up was planned at 1, 4, and 9 months, and
hen yearly for 5 years. The primary end point was the rate
f ischemia-driven target vessel revascularization (TVR)
djudicated by an independent clinical events committee.
ther adjudicated clinical end points included death, myo-
ardial infarction, target lesion revascularization (TLR),
arget vessel failure, major adverse cardiac events (MACE),
nd stent thrombosis, as previously defined (12). Angio-
raphic follow-up was pre-specified in 732 patients at nine
onths. All baseline and follow-up angiograms were ana-
yzed at an independent core laboratory.
tatistical analysis. Examination of gender-based out-
omes was a pre-specified subset analysis. Categorical vari-
bles were compared with chi-square test for trend (for
our-way comparisons) or with the Fisher exact test (for
wo-way comparisons). Continuous variables are presented
s means  1 SD or median with interquartile ranges and
ere compared by the Wilcoxon two-sample test. Survival
stimates were created using Kaplan-Meier methodology,
nd compared using the log-rank test. The influence of
aseline variables on the nine-month rates of angiographic
Abbreviations and Acronyms
CI  confidence interval
MACE  major adverse cardiac events
OR  odds ratio
TLR  target lesion revascularization
TVR  target vessel revascularization
able 1. Baseline Demographic Features According to Gender an
TAXUS Stent
Women Men
187 475
ean age, yrs 66.1  11.4 61.6  10.8
ody surface area, m2 1.82  0.19 2.07  0.19
ypertension, % 78.5 67.7
yperlipidemia, % 68.0 65.5
iabetes, % 33.7 19.4
rior heart failure, % 9.1 4.1
eripheral vascular disease, % 10.1 9.4
enal insufficiency, % 7.1 3.2
istory of coronary artery disease, % 77.0 64.6
rior myocardial infarction, % 27.8 31.6
revious smoker, % 29.8 45.4
nstable angina, % 42.2 33.3 0.03estenosis was evaluated with logistic regression, using entry
nd stay criteria of 0.20 and 0.10, respectively. A Cox
roportional hazard regression was used to identify the
ndependent determinates of TLR and TVR. The variables
ntered into these models included age, smoking status,
iabetes, epicardial coronary artery, previous myocardial
nfarction, hypertension, hyperlipidemia, left ventricular
jection fraction, unstable angina, creatinine clearance, os-
ial location, bend 45°, tortuosity, calcification, lesion
ength, baseline reference vessel diameter, and baseline
inimal luminal diameter, with gender forced into the
odels. All p values are two-sided.
ESULTS
aseline and procedural characteristics. Of the 1,314
andomized patients, 662 were assigned to the paclitaxel-
luting stent (including 475 [71.8%] men and 187 [28.2%]
omen), and 652 were assigned to the bare-metal control
tent (including 472 [72.4%] men and 180 [27.6%]
omen). Gender differences in baseline demographic char-
cteristics according to randomization are detailed in
able 1. In the TAXUS group, women were older than
en, and had more hypertension, diabetes, baseline renal
nsufficiency, unstable angina, and prior congestive heart
ailure, but less smoking. These findings were similar in the
ngiographic subset.
Angiographic characteristics are detailed in Table 2. Left
entricular ejection fraction was greater in women than men
espite more prior congestive heart failure. Women had
maller vessel diameters, but similar lesion lengths com-
ared to men. Procedure-related complications including
issections, abrupt vessel closure (0.3%), and no-reflow
0.7%) were infrequent in both groups. The post-procedural
ngiographic diameter stenosis was similar in men and
omen, and in both randomized groups.
Gender-based differences in the discharge medical regimen
ncluded less use of beta-blockers (63.1% vs. 71.2%, p 0.05)
ndomization Arm
Control Stent
TAXUS vs.
Control
ue Women Men p Value
Women
p Value
Men
p Value
180 472
1 65.2  10.9 60.9  10.7 0.0001 0.45 0.33
01 1.80  0.18 2.08  0.20 0.0001 0.48 0.76
6 80.0 65.5 0.0003 0.79 0.49
64.2 67.3 0.46 0.50 0.58
01 29.4 23.3 0.11 0.43 0.15
11.7 5.8 0.01 0.49 0.23
14.9 8.7 0.02 0.19 0.73
4.6 3.4 0.49 0.37 1.00
5 73.7 63.5 0.02 0.51 0.77
24.4 32.0 0.06 0.47 0.94
03 35.8 51.7 0.0004 0.25 0.06d Ra
p Val
0.00
0.00
0.00
0.58
0.00
0.01
0.78
0.03
0.00
0.34
0.0041.7 29.2 0.003 0.91 0.18
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Gender Differences After Paclitaxel-Eluting Stents April 19, 2005:1180–5nd lipid-lowering (65.2% vs. 75.8%, p  0.007) agents in
omen, but greater use of angiotensin-converting enzyme
nhibitors (57.8% vs. 46.3%, p  0.01). Protocol-mandated
spirin and thienopyridine use was equally high in men and
omen at discharge (99%) and at 30 days (97%); at 9
onths aspirin use was also similar (95%), but thienopyridine
se was lower in women (35.4% vs. 47.7%, p 0.005). There
ere no differences in medication use in patients randomized
o paclitaxel-eluting versus bare-metal stents.
ender-specific clinical outcomes. The 30-day rates of
ACE were similar in men compared to women, random-
zed to either the paclitaxel-eluting stent or the bare-metal
tent (Table 3). At one year, among patients randomized to
he bare-metal stent, the rates of cardiac death, TLR, and
VR were similar between men and women. Women
ssigned to the control stent had a higher incidence of
yocardial infarction at one year than men, though the
verall composite incidences of MACE were similar in men
nd women. Among patients randomized to the paclitaxel-
luting stent, the one-year rates of TLR and TVR were
ignificantly higher in women than men, though there were
o differences in cardiac death, myocardial infarction, or
omposite MACE. By multivariate analysis, female gender
as not an independent predictor of either TLR or TVR
mong patients randomized to the paclitaxel-eluting stent
fter adjustment for differences in baseline characteristics
etween men and women (Fig. 1).
Among women, randomization to the paclitaxel-eluting
tent rather than the control stent resulted in lower one-year
ates of myocardial infarction (66% reduction) and TLR
54% reduction), with a strong trend toward reduced TVR
41% reduction) (Table 3). As a result, target vessel failure
44% reduction) and composite MACE (45% reduction)
ere significantly reduced in women assigned to the
AXUS stent. Men randomized to the paclitaxel-eluting
tent rather than the bare-metal stent had reduced one-year
ates of TLR (80% reduction), TVR (69% reduction), target
essel failure (55% reduction), and MACE (51% reduction).
ender-specific angiographic outcomes. Follow-up an-
iography at nine months demonstrated that the amount of
ate loss was similar in women and men treated with the
aclitaxel-eluting stent, both within the stent and the entire
nalysis segment. As a result, the binary rates of in-stent and
nalysis segment restenosis were also similar in men and
omen after TAXUS stent implantation (Table 4). Ran-
omization to the TAXUS stent rather than the bare-metal
ontrol stent in both men and women resulted in markedly
ess late loss and, therefore, highly significant reductions in
oth in-stent and analysis segment restenosis. Both men
nd women experienced a 70% relative reduction in analysis
egment restenosis with assignment to the TAXUS stent
ather than the control stent. Among women, the only
ndependent predictor of freedom from analysis segment
estenosis at nine months was randomization to the
aclitaxel-eluting stent (odds ratio [OR]  0.28 [95%confidence interval (CI) 0.11 to 0.74], p  0.01). In men,Ta
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ndependent correlate of freedom from restenosis (OR 
.19 [95% CI 0.09 to 0.37], p  0.0001).
ISCUSSION
he present analysis from the TAXUS-IV trial demon-
trates that the overall beneficial effects of the paclitaxel-
luting stent in reducing clinical and angiographic restenosis
re generalizable to female patients. Women assigned to the
AXUS stent, however, did have higher absolute revascu-
arization rates compared to men, a difference that by
ultivariate analysis was driven by the increased incidence
f covariate risk factors for restenosis in women, including
iabetes, smaller reference vessel diameter and body surface
rea, and not by female gender per se. Moreover, the relative
eduction in angiographic restenosis with the TAXUS stent
ompared to the bare-metal control stent was virtually
dentical in women and men.
The influence of gender on the rates of angiographic
estenosis has not been frequently reported from prior
andomized studies, partly due to the under-representation
f women in prospective trials incorporating systematic
ngiographic follow-up. Paradoxically, observational regis-
ry data have generally reported women to have similar or
ower TLR rates compared to men after balloon angioplasty
17–23) and stenting (23–26), despite their consistently
maller vessel size and higher prevalence of diabetes melli-
us, factors that are typically associated with higher reste-
osis and revascularization rates after coronary interventions
21–25). In the absence of systematic angiographic and
linical follow-up, this counterintuitive finding is of uncer-
ain clinical significance. Referral bias, in which women are
ess likely to be referred or undergo follow-up angiography
r revascularization due to gender-based discrepancies in
able 3. Clinical Outcomes at 30 Days and 1 Year
TAXUS Stent
Women Men p Va
187 475
0 days, %
Major adverse cardiac events 2.1 3.2 0.4
Cardiac death 0.0 0.4 0.3
Myocardial infarction 2.1 2.7 0.6
Target vessel revascularization 0.0 0.0 —
Stent thrombosis 0.0 0.4 0.3
year, %
Major adverse cardiac events 13.5 9.9 0.2
Target vessel failure 13.0 8.8 0.1
Cardiac death 0.5 1.7 0.2
Myocardial infarction 2.7 3.8 0.4
Target lesion revascularization 7.6 3.2 0.0
Target vessel revascularization 10.8 5.7 0.0
Repeat coronary intervention 9.2 4.1 0.0
Bypass graft surgery 2.2 1.6 0.5
Stent thrombosis 0.0 0.8 0.2ither patient or physician interpretation of symptoms or toninvasive tests may explain the lower observed TLR rates
n women compared with men in uncontrolled studies. Two
tudies of elective stenting, in contrast, found female gender
o be predictive of higher rates of restenosis and revascular-
zation (27,28).
A pooled analysis of seven prospective, controlled inves-
igational device exemption stent trials has been performed
hat included 7,171 patients (2,179 women and 4,992 men)
ndergoing elective bare-metal stent implantation in 3.0 to
.0 mm vessels (23). Systematic angiographic and clinical
ollow-up was mandated by individual protocols. This study
emonstrated no differences in TVR one year after bare-
etal stenting between men and women (12% women vs.
1% men, p  NS).
Given the potential for referral bias, the higher unad-
usted one-year rates of TLR and TVR in women compared
o men treated with the paclitaxel-eluting stent in the
AXUS-IV trial (a trend not seen with the bare-metal
tent) is at first glance a notable finding. However, by
ultivariate analysis, gender was not an independent pre-
ictor of TLR or TVR after TAXUS stent implantation.
ather, the higher repeat revascularization rates in women
eceiving the TAXUS stent were explained by the more
requent presence of confounding variables in female pa-
ients, including diabetes, smaller reference vessel diameter
nd body surface area, that were more directly responsible
or clinical restenosis. Moreover, the TAXUS stent resulted
n a nearly identical 70% reduction in angiographic reste-
osis in both men and women. Indeed, among women,
andomization to the TAXUS stent was the only indepen-
ent determinate predicting a reduction in restenosis.
Importantly, the benefits of the paclitaxel-eluting stent in
omen in terms of reducing restenosis were achieved without
vident safety issues such as stent thrombosis. On the contrary,
Control Stent TAXUS vs. Control
Women Men p Value
Women
p Value
Men
p Value
180 472
3.3 2.1 0.37 0.48 0.32
0.0 0.6 0.28 — 0.65
3.3 1.9 0.28 0.48 0.39
0.0 0.4 0.38 — 0.16
0.0 0.8 0.22 — 0.41
22.7 19.0 0.35 0.02 0.0001
21.6 18.6 0.45 0.03 0.0001
1.8 1.1 0.53 0.30 0.41
7.9 3.4 0.02 0.03 0.73
14.9 15.2 0.88 0.02 0.0001
17.5 17.0 0.95 0.07 0.0001
15.2 13.4 0.69 0.08 0.0001
2.2 4.7 0.15 0.95 0.0044
0.0 1.1 0.17 — 0.73lue
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Gender Differences After Paclitaxel-Eluting Stents April 19, 2005:1180–5omen receiving the TAXUS stent rather than a bare-metal
tent, which, along with reductions in TLR and TVR, con-
ributed to significantly lower rates of target vessel failure and
omposite MACE in women. Thus, although additional
tudies would be welcome to investigate the gender-based
mpact of clinical and angiographic restenosis after drug-
luting stents, the results of the present analysis suggests that
he paclitaxel-eluting stent is effective in reducing restenosis
nd enhancing event-free survival in women as well as men.
tudy limitations. Though pre-specified, the present post-
oc subset analysis must be considered hypothesis-
enerating. The numbers of women studied were insuffi-
ient, and the study was underpowered to definitively
etermine whether the TAXUS stent reduces clinical revas-
ularization in women, which may contribute to why
omen compared to men treated with the TAXUS stent
igure 1. Multivariate predictors of one-year target lesion revascularization
aclitaxel-eluting stent. CI  confidence interval; HR  hazard ratio.ad higher clinical but not angiographic revascularization oates. In addition, the results of this analysis apply only to
he patient cohort defined by the protocol of the TAXUS
rial. For example, no conclusions can be drawn regarding
ptimal treatment of women with more diffuse disease,
cute myocardial infarction, or those requiring multivessel
ntervention. Furthermore, whether drug-eluting stents
ther than the polymer-based paclitaxel-eluting stent would
e more or less effective in women is unknown.
onclusions and clinical implications. The TAXUS stent
afely reduces clinical and angiographic restenosis, and im-
roves survival free from MACE in both men and women.
bsolute clinical restenosis rates may be higher in women than
en receiving the TAXUS stent, though such an observation
s explained by the presence of other risk factors for restenosis
fter drug-eluting stents in women, rather than gender per se.
oreover, as the only variable identifiable as being predictive
and target vessel revascularization (bottom) in patients randomized to the(top)f freedom from restenosis was assignment to the paclitaxel-
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hould be preferentially used in women (as well as men) with
esions meeting the enrollment criteria of the TAXUS-IV trial.
eprint requests and correspondence: Dr. Gregg W. Stone,
ardiovascular Research Foundation, 55 East 59th Street, 6th
loor, New York, New York 10022. E-mail: gstone@crf.org.
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